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810 The Journal of Thoracic and CardioObjective: This study was undertaken to evaluate the effect of triiodothyronine
replacement on the early postoperative course of neonates undergoing aortic arch
reconstruction.
Methods: We performed a randomized, double-blind, placebo-controlled trial of
triiodothyronine supplementation in neonates undergoing either a Norwood proce-
dure or two-ventricle repair of interrupted aortic arch and ventricular septal defect.
Patients were assigned to receive a continuous infusion of triiodothyronine (0.05
/kg/h) or placebo for 72 hours after cardiopulmonary bypass. Primary end points
were a composite clinical outcome score and cardiac index at 48 postoperative
hours.
Results: We enrolled 42 patients (triiodothyronine n  22, placebo n  20).
Baseline characteristics were similar in the treatment groups. Study drug was
discontinued prematurely because of hypertension (n  1) and ectopic atrial
tachycardia (n  1), both cases in the triiodothyronine group. Free and total
triiodothyronine levels were higher in the triiodothyronine group than in the placebo
group at 24, 48, and 72 postoperative hours (P  .001). The median clinical
outcome scores were 2.0 (range 0-4) with triiodothyronine and 2.0 (range 0-7) with
placebo (P  .046). Compared with those in the placebo group, neonates assigned
to triiodothyronine had shorter median time to negative fluid balance (2.0 vs 2.5
days, P  .027). Cardiac index values were 2.11  0.64 L/min · m2 with triiodo-
thyronine and 2.05  0.72 L/min · m2 with placebo (P  .81). Heart rate and
diastolic blood pressure were not influenced by triiodothyronine supplementation,
but systolic blood pressure was higher in the triiodothyronine group (P  .001). No
serious adverse events were attributed to triiodothyronine administration.
Conclusion: Triiodothyronine supplementation was safe and resulted in more rapid
achievement of negative fluid balance after aortic arch reconstruction. Cardiac index
at 48 hours was not significantly improved.
L ow cardiac output syndrome is a common complication of neonatal cardiacsurgery.1 Contributing factors include myocardial ischemia during aorticcrossclamping, the effects of cardioplegia, the inflammatory reaction to
cardiopulmonary bypass (CPB), hypothermia, and reperfusion injury.2 Low cardiac
vascular Surgery ● September 2005
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Doutput in the postoperative patient continues to be a source
of significant morbidity, sometimes warranting the use of
mechanical circulatory support.2 Hoffman and colleagues3
demonstrated that the incidence of low cardiac output syn-
drome in children undergoing corrective cardiac procedures
is reduced by high-dose milrinone, a phosphodiesterase
inhibitor. Additional therapies that both support the myo-
cardium and lower systemic vascular resistance after con-
genital heart surgery would be valuable in treating the
neonates at highest risk.
Thyroid hormones have important effects on cardiovas-
cular function.4 These include an increase in cardiac con-
tractility5 and a lowering of systemic vascular resistance
mediated by dilation of resistance arterioles in the periph-
eral circulation.6 However, levels of triiodothyronine (T3),
the biologically active hormone in cardiac myocytes, are
significantly depressed in infants and older children after
CPB.7,8 Low T3 levels in the early postoperative period
therefore may contribute to the evolution of low cardiac
output syndrome. Previous studies have suggested that ne-
onates and patients undergoing more lengthy procedures
may benefit from T3 replacement, with improved cardiac
output and more favorable intensive care unit (ICU) acuity
scores.9,10
The purpose of this study was to evaluate the effect of T3
replacement on the early postoperative course in a homo-
geneous group of high-risk neonates undergoing either the
Norwood procedure or repair of ventricular septal defect
and interrupted aortic arch. Specifically, we tested the hy-
pothesis that T3 replacement plus conventional therapy
would be associated with better early postoperative outcome
than would placebo plus conventional therapy.
Methods
Study Participants
A patient satisfied the inclusion criteria if he or she was (1) a
neonate who had a diagnosis of hypoplastic left heart syndrome or
another functional single-ventricle lesion with aortic arch obstruc-
tion and was scheduled to undergo the Norwood procedure with
either a modified Blalock-Taussig shunt or a right ventricle–to–
pulmonary artery conduit or (2) a neonate who had ventricular
septal defect and interrupted aortic arch and was scheduled to
undergo two-ventricle repair. Patients were excluded if they had
TABLE 1. Composite clinical outcome score
Clinical variable
Time until negative fluid balance first achieved (d)
Time until sternal closure (d)
Time until first extubation (d)
Each patient received a score between 0 and 6 by adding the individual sc
or required extracorporeal membrane oxygenation support. d, Days.birth weight lower than 2.3 kg, preoperative tachyarrhythmia,
The Journal of Thoraciclinical sepsis confirmed by culture, serum creatinine greater than
133 mol/L (1.5 mg/dL) within 24 hours of surgery, or a known
thyroid or metabolic disorder. Written, informed consent was
required from the parents or legal guardians before randomization.
Study Design
The study had two phases. Phase 1 was an open-label, dose-finding
phase. The first 5 patients received an infusion of T3 (King
Pharmaceuticals, Cary, NC) for 72 hours beginning at the com-
pletion of CPB at a dose of 0.0625 g/kg/h); 2 subsequent patients
received a dose of 0.05 g/kg/h) on the basis of an analysis of
serum T3 levels in the initial 5 patients. Phase 2 was a randomized,
double-blind, placebo-controlled, single-center study. Randomiza-
tion was performed with a computer-based random-number gen-
erator in permuted blocks of 2 and 4 and was stratified by surgeon
and surgical procedure (Norwood palliation or ventricular septal
defect and interrupted aortic arch repair). Eligible patients whose
parents consented to study participation were randomly assigned
preoperatively to receive a 72-hour infusion of either T3 (0.05
g/kg/h) or placebo (0.9% sodium chloride solution). Vasoactive
infusions and other routine postoperative care were administered at
the discretion of the surgical and ICU teams. Levels of total and
free T3, total and free thyroxine (T4), thyroid-stimulating hormone,
and T3 resin uptake were measured before initiation of CPB; at the
end of CPB before starting study drug; at 24, 48, and 72 postop-
erative hours; and at 7 and 14 postoperative days. Total T3 and T4
concentrations were measured by competitive chemiluminescent
immunoassay, free T3 was measured by equilibrium tracer dialy-
sis, and free T4 was measured by direct dialysis. All specimens
were analyzed at a core laboratory (Nichols Institute, San Juan
Capistrano, Calif).
Surgical Techniques
Patients with a functional single ventricle and aortic arch obstruc-
tion underwent a Norwood procedure with a modified Blalock-
Taussig shunt11 or a right ventricle–to–pulmonary artery polytet-
rafluoroethylene conduit (Gore-Tex conduit; W. L. Gore &
Associates, Inc, Flagstaff, Ariz)12,13 at the discretion of the attend-
ing surgeon. Patients with interrupted aortic arch and two func-
tional ventricles underwent complete repair as previously de-
scribed.14 A pH-stat perfusion strategy was used in all patients.
Methylprednisolone (30 mg/kg) was administered at initiation of
CPB, and deep hypothermic circulatory arrest was used routinely,
during which core temperatures were lowered to 18°C. Continuous
ultrafiltration was used as patients were being rewarmed and
Score
0 1 2
3 4-5 6
2 3-4 5
4 5-8 9
for each clinical variable. A score of 7 was assigned to patients who diedoresweaned from CPB.
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DStudy End Points
The primary end points were as follows: (1) a composite clinical
score created for the trial and (2) cardiac index (CI) measured at 48
postoperative hours. The composite clinical score, derived through
consensus by experts in pediatric cardiac intensive care, consisted
of variables that reflect the rate of early postoperative recovery
(Table 1). Lower scores represented a more favorable postopera-
tive course. CI was measured at 48 postoperative hours because the
nadir in T3 level has been shown to occur at this time in pediatric
cardiac patients,8 so we believed that we would be most likely to
detect a difference between treatment groups at that point. CI was
determined by simultaneously measuring oxygen consumption
(CO2) with a previously validated real-time gas-exchange tech-
nique,15 hemoglobin (in grams per liter), venous oxygen saturation
from the superior vena cava (SsvcO2) and arterial oxygen satura-
tion (SaO2) by co-oximetry, and entering values into the following
formula: Qs  CO2/[(SaO2  SsvcO2)  1.36  hemoglobin 
100], where Qs is the systemic cardiac output. Patients were
sedated, paralyzed, and mechanically ventilated, and had a cuffed
tracheal tube to prevent air leak so that the accuracy of CO2
measurements could be optimized. The inspired fraction of oxygen
was not higher than 0.40 at the time of these measurements.
Secondary end points included serum lactate levels at 12, 24,
TABLE 2. Patient characteristics
Patient characteristic
Birth weight (kg)
Body surface area (m2)
Male sex (No.)
Gestational age (wk)
Apgar score at 1 min
Apgar score at 5 min
Age at surgery (d)
Diagnosis (No.)
Hypoplastic left heart syndrome
Other single ventricle with arch obstruction
Interrupted aortic arch
Ethnicity (No.)
White
Black
Other
Prenatal cardiac diagnosis (No.)
Preoperative serum creatinine (mol/L)
Preoperative serum lactate (mmol/L)
Mechanically ventilated before surgery (%)
Extubated before surgery* (No.)
Surgical procedure (No.)
Norwood with aortopulmonary shunt
Norwood with right ventricle–pulmonary artery shunt
Two-ventricle repair of interrupted aortic arch
Duration of CPB (min)
Duration of aortic crossclamping (min)
Duration of circulatory arrest (min)
Results are presented as mean  SD as appropriate. *Percentage is witand 48 hours after the termination of CPB, incidence of serious
812 The Journal of Thoracic and Cardiovascular Surgery ● Septadverse events (recorded until the time of hospital discharge),
oxygen delivery (DO2),16 and the ratio DO2/CO2, which reflects the
relative excess of DO2.17 DO2 was calculated as the product of
CaO2  Qs, where CaO2  1.36  hemoglobin  SaO2  100.
Inotrope score was determined for the initial 5 postoperative days,
as modified from Wernovsky and coworkers.1
Serum cortisol was measured immediately before CPB and at
24 and 48 hours after the operation. Ionized calcium was measured
at 12, 24, and 48 postoperative hours.
Patient Safety
Criteria for premature termination of the study drug infusion were
as follows: (1) sinus tachycardia (200 beats/min) lasting longer
than 15 minutes, (2) high systolic blood pressure (90 mm Hg) for
longer than 15 minutes, or (3) any tachyarrhythmia lasting longer
than 30 seconds. An external Data Safety and Monitoring Board
was established to oversee the safety of study participants. The
study was approved by the Committee on Clinical Investigation at
Children’s Hospital Boston.
Statistical Analysis
Sample-size calculations were based on the primary study end
T3
(n  22)
Placebo
(n  20) P value
3.3 0.5 3.4 0.6 .53
0.22 0.02 0.22 0.03 .99
13 (59%) 14 (70%) .53
38.9 1.9 38.4 1.5 .40
7.4 1.5 7.0 2.1 .41
8.3 1.2 8.4 0.9 .84
7.1 4.0 5.8 2.9 .21
17 (77%) 16 (80%) .999
3 (14%) 2 (10%)
2 (9%) 2 (10%)
20 18 .79
2 1
0 1
8 (36%) 10 (50%) .53
46.0 15.0 42.4 18.6 .50
1.9 1.0 1.8 0.7 .80
11 (50%) 13 (65%) .37
2 (18%) 3 (23%) .999
8 (36%) 8 (40%) .999
12 (55%) 10 (50%)
2 (9%) 2 (10%)
111 47 98  32 .31
55 24 63 19 .25
36 19 50 18 .014
rence to patients mechanically ventilated before surgery.point of CI at 48 postoperative hours. Assuming that mean CI
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Dwould be 2.0 L/min · m2 with SD 0.5 L/min · m2 in the placebo
group, a sample size of 21 patients in each arm was required to
detect a 25% increase in CI in the T3 group, with a 2-tailed,
2-sample t test conducted at the .05 level with 90% power. Anal-
yses were performed on an intent-to-treat basis. Comparisons of
preoperative, intraoperative, and postoperative variables between
treatment groups, including the primary and secondary outcome
variables, were made with linear regression analysis or the Wil-
coxon rank sum test for continuous variables, the Wilcoxon rank
sum test for ordinal variables, and the Fisher exact test for cate-
goric variables. Repeated measures analysis of variance was used
for comparisons of serial measurements of heart rate, blood pres-
sure, and thyroid function tests across time. Analyses were per-
formed with Statistical Analysis Systems software, version 9 (SAS
Institute, Inc, Cary, NC).
Results
Between July 2002 and April 2004, a total of 61 patients
were eligible for study participation. Participation was de-
clined by parents or guardians of 5 patients, and insufficient
time to enroll before surgery prevented participation of an
additional 6 patients. The remaining 50 patients were en-
rolled, 7 to the open-label phase and 43 to the randomized
phase. A single patient was withdrawn from the randomized
phase before initiation of study drug because extracorporeal
membrane oxygenation support was required in the operat-
ing room after CPB. The remaining 42 patients (T3 n  22,
placebo n  20) form the study group for analysis. The
patient who was withdrawn had been randomly assigned to
the placebo arm; she eventually died and accounts for the
only in-hospital death.
The first 5 patients of the open-label phase received a T3
dose of 0.0625 g/kg/h and had mean free T3 levels of 7.3
Figure 1. T3 levels measured in the operating room bef
and 7 and 14 postoperative days. Error bars represen
ranges (Nichols Institute, San Juan Capistrano, Calif).
T3 group at 24, 48, and 72 postoperative hours (P < .0 4.0 pmol/L at 24 postoperative hours, 8.7  0.4 pmol/L
The Journal of Thoraciat 48 hours, and 7.9 2.4 pmol/L at 72 hours (normal range
4.3-8.0 pmol/L; Nichols Institute, San Juan Capistrano,
Calif). The next 2 patients received a dose of 0.05 g/kg/h)
and had mean free T3 levels of 6.0 pmol/L (24 hours), 7.7
pmol/L (48 hours), and 4.7 pmol/L (72 hours). The latter 2
patients formed the basis for a T3 dose of 0.05 g/kg/h in
the randomized phase.
There were no statistically significant differences be-
tween the two treatment groups with respect to demographic
variables, diagnosis, surgical procedure, or duration of CPB
(Table 2). The proportion of patients who underwent Nor-
wood procedures with a right ventricle–to–pulmonary artery
conduit was comparable in the T3 and placebo groups. The
duration of deep hypothermic circulatory arrest was shorter
in the T3 group than in the placebo group (Table 2).
The study drug was stopped 2 hours prematurely in 1
patient because of mild, brief hypertension; the drug was
stopped 33 hours prematurely in a second patient because of
ectopic atrial tachycardia, which was transient (a 7-minute
episode with a maximum heart rate of 231 beats/min) and
hemodynamically well tolerated. The patient with ectopic
atrial tachycardia had subsequent episodes of tachyarrhyth-
mia as late as 6 days after termination of study drug. Both
patients were in the T3 arm. Neither patient had a serious
adverse event. Temporary loss of peripheral venous access
or lack of availability of study drug resulted in an interrup-
tion of study drug infusion in 3 patients in the T3 arm and
1 patient in the placebo arm. No interruption lasted longer
than 2 hours. All other patients received the study drug as
intended.
Total and free T3 levels were significantly higher in the
nd after CPB and at 24, 48, and 72 postoperative hours
confidence intervals. Shaded zones indicate normal
T3 levels (A) and free T3 levels (B) were higher in theore a
t 95%
Total
01).T3 group than in the placebo group at 24, 48, and 72
c and Cardiovascular Surgery ● Volume 130, Number 3 813
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Dpostoperative hours but were similar between treatment
groups immediately before and after CPB and at 7 and 14
postoperative days (Figure 1, A and B). Levels of total and
free T4, thyroid-stimulating hormone, and T3 resin uptake
did not differ between the two groups at any time before or
after surgery (data not shown).
Composite clinical outcome score (Table 1) was a pri-
mary end point. The median scores were 2.0 (range 0-4) in
the T3 group and 2.0 (range 0-7) in the placebo group, a
significant difference (P  .046) that arose from a differ-
ence in the distribution of values; the only patients with a
score greater than 4 were in the placebo group (Table 3).
The median time until a negative fluid balance was first
achieved was lower in the T3 group, at 2.0 days (range 1-4
days), than in the placebo group (2.5 days, range 2-3 days,
P  .027). After controlling for duration of circulatory
arrest, the magnitude of this effect did not change (P .05).
Time until sternal closure and duration of mechanical ven-
tilation were not significantly different between the treat-
ment groups.
TABLE 3. Results of the composite clinical outcome score
Outcome
Composite clinical score
Time until first negative fluid balance (d)
Time until sternal closure (d)
Time until first extubation (d)
In-hospital death* (No.)
Extracorporeal membrane oxygenation (No.)
Each subcomponent of the clinical score is also presented. Results are pr
to the placebo group died at home 5 weeks after hospital discharge; 1 pat
initiation of study drug and died in the hospital.
Figure 2. Systolic blood pressure (A) was higher in the 3
as was mean blood pressure (B) (P  .02). Error bars repre
814 The Journal of Thoracic and Cardiovascular Surgery ● SeptAlthough our trial was designed with CI as one of the
two primary end points, its measurement was not feasible in
9 patients in the T3 group and 5 patients in the placebo
group because of unreliable CO2 data (n  10) or lack of a
superior vena cava blood sample at 48 postoperative hours
(n  4). Among patients in whom CI could be measured,
the mean values at 48 postoperative hours were 2.11 0.64
L/min · m2 in the T3 group and 2.05  0.72 L/min · m2 in
the placebo group (P  .81). The mean arterial pH was
similar between the T3 and placebo groups when CI was
measured (7.44  0.05 and 7.43  0.04, respectively, P 
.64), as was the mean PaCO2 (49.4  6.30 mm Hg and 47.3
 7.13 mm Hg, respectively, P  .33).
Systolic blood pressure was significantly higher in the T3
group (P  .001; Figure 2, A), as was mean blood pressure
(P  .02; Figure 2, B). However, heart rate and diastolic
blood pressure were not different between treatment groups
(data not shown).
DO2 values at 48 postoperative hours were 342  109
mL/(min · m2) in the T3 group and 321  108 mL/
3
22)
Placebo
(n  20) P value
0-4) 2.0 (0-7) .046
1-4) 2.5 (2-3) .027
0-6) 4.0 (0-6) .14
3-17) 6.0 (4-13) .38
0 0 .999
0 2 (10%) .22
ed as median with range as appropriate. *One patient randomly assigned
as randomly assigned to the placebo group but excluded post hoc before
roup (P < .001) during the early postoperative period,T
(n 
2.0 (
2.0 (
2.5 (
6.0 (
esent
ient wT g
sent 95% confidence intervals.
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D(min · m2) in the placebo group (P  .62). CO2 values,
measured at the same time, were 110 22 mL/(min · m2) in
the T3 group and 108  24 mL/(min · m2) in the placebo
group (P .82). The DO2/CO2 ratios were also equivalent at
3.20  0.91 in the T3 group and 3.22  1.31 in the placebo
group (P  .96).
The mean 5-day inotrope scores were 63.2 32.4 mg/kg
in the T3 group and 69.1 32.3 mg/kg in the placebo group
(P  .56). Mean inotrope scores at 12, 24, and 48 hours
were also similar between treatment groups (data not
shown). The median ICU stays were 7.5 days (range 4-47
days) in the T3 group and 8.5 days (range 5-96 days) in the
placebo group (P  .52). The median total hospital stays
were 16.5 days (range 8-95 days) in the T3 group and 18
days (range 9-112 days) in the placebo group (P  .59).
Median times until enteral feeding was started were 4 days
(range 2-7 days) in the T3 group and 5 days (range 2-7 days)
in the placebo group (P  .35). There were no differences
in serum lactate, ionized calcium, or cortisol between
groups either before or after the operation (data not shown).
The incidence of serious adverse events, including car-
diac arrest, renal failure, and infectious complications, did
not differ between treatment groups. No serious adverse
events were attributed directly to the administration of study
medication.
Discussion
In a population of neonates undergoing high-risk open heart
surgery, we found that postoperative treatment with T3 for
72 hours was associated with significantly better clinical
outcome scores than was treatment with placebo, with the
difference attributable to more rapid achievement of a neg-
ative fluid balance in the T3 group. Systolic and mean blood
pressures were higher in T3-treated patients. For technical
reasons, we were unable to measure CI in a third of the
patients; however, among those in whom CI was measured,
we found no difference between treatment groups. T3 sup-
plementation did not increase CO2 at the expense of DO2 and
was not associated with important adverse events. To our
knowledge, this study represents the largest prospective
clinical trial published to date of T3 supplementation in
neonates after cardiac surgery.
Previous studies on T3 supplementation in pediatric pa-
tients have suggested that its administration may benefit
recovery after cardiac surgery. Mainwaring and col-
leagues18 gave two bolus doses of T3 after the Fontan
procedure to 10 children aged 19 to 42 months. Relative to
a historical control group, the T3 group had a significantly
shorter period of mechanical ventilation. Bettendorf and
associates10 randomly allocated 40 children undergoing a
wide variety of cardiac procedures to receive bolus dosing
of T3 or placebo. Patients in the T3 group had lower Ther-
apeutic Intervention Scoring System (TISS) scores than did
The Journal of Thoracithose in the placebo arm. Cardiac output was higher in the
treatment group 24 hours after surgery, as measured by
Doppler echocardiography. Chowdhury and coworkers9
randomly assigned 28 children aged 0 to 18 years to a 5-day
continuous infusion of T3 (0.05-0.15 g/[kg · h]) or pla-
cebo. Among the subset of neonates (n  9), the T3 group
had lower TISS scores and lower inotrope requirements.
The T3 group also had a trend toward higher mixed venous
oxygen saturations, fewer days of mechanical ventilation,
and a shorter postoperative stay.
Our findings may differ from those of other authors on
the basis of several factors. We used different primary
outcome measures (a composite clinical outcome score and
CI determined by real-time gas-exchange measurement of
CO2), and we measured CI at 48 rather than 24 postoperative
hours. In addition, we administered a continuous infusion of
T3 rather than bolus dosing, without adjustment of the
infusion rate according to T3 levels. Only one previous
pediatric study has used a continuous infusion,9 and those
investigators adjusted the infusion rate to maintain serum
total T3 levels within a target range; the doses used were
also as great as 3 times the dose we used. However, we
achieved T3 levels in the treatment group that were within
normal range and were significantly higher than in the
placebo group.
The more rapid achievement of a negative fluid balance
in children treated with T3 may have several explanations.
Thyroid hormones are important for the normal function of
all organs, and low free T3 levels in the placebo group may
have impaired intrinsic renal function. Alternatively, higher
systolic blood pressures in the T3 group may have contrib-
uted to improved renal perfusion and glomerular filtration.
The difference in circulatory arrest times between the T3
and placebo groups, however, does not explain the differ-
ence in time to negative fluid balance.
Limitations
The clinical outcome score used has not been previously
validated. Nonetheless, our score discriminated patients re-
ceiving T3 infusion from those receiving placebo. The in-
ability to measure CI in an important percentage (33%) of
subjects was also a limitation. Although free from the as-
sumptions inherent in measuring CI by Doppler echocardi-
ography,19 direct measurement of CO2 by real-time gas
exchange requires a sedated, mechanically ventilated pa-
tient who has not had a change in hemodynamic or respi-
ratory status for at least 1 hour. Furthermore, “true” mixed
venous oxygen saturation could not be measured in patients
undergoing the Norwood procedure. We approximated this
variable by measuring SsvcO2. This value is influenced by
cerebral blood flow, which in turn is influenced not only by
cardiac output but also by serum pH and PaCO2.20 However,
arterial pH and PaCO2 did not differ between the T3 and
c and Cardiovascular Surgery ● Volume 130, Number 3 815
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Dplacebo groups at the time of CI determination. Finally,
transcutaneous absorption of iodine, well described in in-
fants,21,22 is a potential confounder of our study findings.
Although all patients were exposed to iodine for skin anti-
sepsis during the perioperative period, no attempt was made
to quantify either the volume of iodine used or the duration
of exposure on a per patient basis.
We observed a shorter ICU stay and total hospitalization
in the T3 group. Although these findings were not statisti-
cally significant, our study lacked sufficient power to dem-
onstrate a significant difference in these end points. A
larger, multicenter study might be able to find an impact of
T3 supplementation on the durations of ICU and hospital
stay. The potential benefit of T3 supplementation in T3-
deficient patients who are further out from surgery and yet
remain critically ill is also unknown.
In summary, we found that T3 supplementation in neo-
nates after high-risk cardiac surgery was safe and resulted in
favorable composite clinical outcome scores in the early
postoperative period as a result of more rapid achievement
of a negative fluid balance. CO2 was not increased at the
expense of DO2. Systolic and mean blood pressures were
higher in patients who received T3. However, CI measured
at 48 postoperative hours was not influenced by T3 infusion.
The routine use of T3 in neonates after cardiac surgery is not
supported by our findings; however, patients with oliguria
and marginal blood pressure may benefit. Larger, multi-
center studies should examine the role of T3 repletion in
children undergoing other congenital heart procedures and
the impact of T3 supplementation in patients with prolonged
critical illness after neonatal cardiac surgery.
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